SCHEMBL3358099

SCHEMBL3358099

COC(=O)C1C(/C=C(/F)Cl)C1(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.44
KMT2A Q03164 4/20 0.39
TDP1 Q9NUW8 4/20 0.39
MEN1 O00255 3/20 0.39
TSHR P16473 3/20 0.36
ATM Q13315 2/20 0.35
ADRA2A P08913 1/20 0.35
CNR1 P21554 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
HPGD P15428 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL808827 1.00 LMNA (0.44) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL5706690 1.00 LMNA (0.44) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL4433146 0.87 LMNA (0.47) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL293469 0.87 LMNA (0.47) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL4433144 0.87 LMNA (0.47) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL18783983 0.87 LMNA (0.47) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL10938588 0.87 LMNA (0.47) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL9862228 0.85 LMNA (0.50) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL808904 0.85 LMNA (0.50) LMNAKMT2ATDP1MEN1TSHR
SCHEMBL10828300 0.85 LMNA (0.50) LMNAKMT2ATDP1MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1783111-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-04-08 EP disclosed
US-7705165-B2 Method for producing optically active cyclopropanecarboxylate compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-27 US disclosed
US-7671210-B2 Process for production of optically active cyclopropanecarboxylate compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-02 US disclosed
EP-1783130-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND SUMITOMO CHEMICAL CO (JP) 2009-12-30 EP disclosed
US-20090048450-A1 Process for production of optically active cyclopropanecarboxylate compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-19 US disclosed
US-20080027235-A1 Method for Producing Optically Active Cyclopropanecarboxylate Compound SUMITOMO CHEMICAL COMPANY, LIMITED 2008-01-31 US disclosed
EP-1783111-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-05-09 EP disclosed
EP-1783130-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027235-A1 Method for Producing Optically Active Cyclopropanecarboxylate Compound ACSL6, AOC1, CA6 LMNA 4253/4885KMT2A 4040/4885TDP1 3949/4885
US-20090048450-A1 Process for production of optically active cyclopropanecarboxylate compound CBR3, C9, CBR1 LMNA 3700/4885KMT2A 4416/4885TDP1 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.